
Sign up to save your podcasts
Or
GLP-1 receptor agonists are revolutionizing treatment for diabetes and obesity, but their impact on the gastrointestinal tract demands careful clinical attention. Dr. Peter Buch is joined by Dr. Michael Camilleri, Professor of Medicine at the Mayo Foundation for Medical Education and Research in Rochester, Minnesota, to discuss key findings on gastrointestinal side effects, procedural risks, and the impacts of GLP-1 receptor agonists on the fields of gastroenterology and hepatology.
4.7
1818 ratings
GLP-1 receptor agonists are revolutionizing treatment for diabetes and obesity, but their impact on the gastrointestinal tract demands careful clinical attention. Dr. Peter Buch is joined by Dr. Michael Camilleri, Professor of Medicine at the Mayo Foundation for Medical Education and Research in Rochester, Minnesota, to discuss key findings on gastrointestinal side effects, procedural risks, and the impacts of GLP-1 receptor agonists on the fields of gastroenterology and hepatology.
7 Listeners
69 Listeners
1 Listeners
3 Listeners
3 Listeners
0 Listeners
6 Listeners
14 Listeners
0 Listeners
2,430 Listeners
3,332 Listeners
111,785 Listeners
1,090 Listeners
3,363 Listeners
7,928 Listeners
185 Listeners
248 Listeners
247 Listeners
366 Listeners
33 Listeners
16 Listeners
11 Listeners